Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbinafine plus Amycor Onychoset/Amycor cream versus terbinafine alone for toenail onychomycosis with matrix involvement
2009-012208-18Phase 3Active
- Sponsor
- Merck Serono
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Terbinafine, bifonazole + urea, bifonazole and urea in onychomycosis (2 arms), sponsored by Merck Serono. Primary endpoint: Responder rate on the target nail at 12 months. Started Jun 2009; status: active.
02
Drugs
Terbinafinebifonazole + ureabifonazoleurea
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2009-012208-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012208-18.